Treatment of Uveitis by In Situ Administration of Ex Vivo–Activated Polyclonal Regulatory T Cells
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
CD4+CD25+Foxp3+ regulatory T (Treg) cell therapy is a promising approach for the treatment of autoimmune diseases. To be effective, Treg cells should be in an activated state in the target tissue. This can be achieved by systemic administration of Ag-specific Treg cells, which are difficult to produce in conditions that can be translated to the clinic. In this paper, we propose an alternative approach consisting of in situ injection of preactivated polyclonal Treg cells that would exert bystander suppression in the target tissue. We show that polyclonal Treg cells suppressed uveitis in mice as efficiently as Ag-specific Treg cells but only when preactivated and administered in the vitreous. Uveitis control was correlated with an increase of IL-10 and a decrease of reactive oxygen species produced by immune cell infiltrates in the eye. Thus, our results reveal a new mechanism of Treg cell–mediated suppression and a new Treg cell therapy approach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both systemic and intravitreal administration of pre-activated Tregs can suppress cell-mediated non-infectious uveitis in animal models (Terrada et al., 2006; Gr ´ egoire et al., 2016).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Grégoire et al., 2016
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737 · cited 1×
“TNF was a good candidate because anti-TNF drugs have therapeutic effects on uveitis in mice and patients (24, 25), and IL-10 reduced production of TNF by myeloid cells (26).”
BackgroundBennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Beyond oxidative stress: an immunologist's guide to reactive oxygen species
Nathan, C., & Cunningham-Bussel, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3423 · Cited by 1,619
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,568
Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease
Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., Shimizu, J., Takahashi, T., & Nomura, T. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00427.x · Cited by 1,555
Sena, L. A., Li, S., Jairaman, A., Prakriya, M., Ezponda, T., Hildeman, D. A., Wang, C.-R., Schumacker, P. T., Licht, J. D., Perlman, H., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.020 · Cited by 1,338
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific
Thornton, A. M., & Shevach, E. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.183 · Cited by 1,229
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L., McDevitt, H., Bonyhadi, M., & Bluestone, J. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040139 · Cited by 1,221
Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis
Komatsu, N., Okamoto, K., Sawa, S., Nakashima, T., Oh-hora, M., Kodama, T., Tanaka, S., Bluestone, J. A., & Takayanagi, H. (2014) · Nature Medicine · doi:10.1038/nm.3432 · Cited by 1,153
Cited by
Immune Privilege and Eye-Derived T-Regulatory Cells
Keino, H., Horie, S., & Sugita, S. (2018) · Journal of Immunology Research · doi:10.1155/2018/1679197 · Cited by 163
Regulatory T cell therapy for type 1 diabetes: May the force be with you
Gitelman, S. E., & Bluestone, J. A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.011 · Cited by 73
Tolerance Induction in Relation to the Eye
Gery, I., & Caspi, R. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02304 · Cited by 57
Plasmacytoid dendritic cells in the eye
Jamali, A., Kenyon, B. M., Ortiz, G., Abou-Slaybi, A., Sendra, V. G., Harris, D. L., & Hamrah, P. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100877 · Cited by 53
Wildner, G., & Diedrichs‐Möhring, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00758-z · Cited by 52
Local Delivery of Regulatory T Cells Promotes Corneal Allograft Survival
Shao, C., Chen, Y., Nakao, T., Amouzegar, A., Yin, J., Tahvildari, M., Lužnik, Z., Chauhan, S. K., & Dana, R. (2018) · Transplantation · doi:10.1097/tp.0000000000002442 · Cited by 40
Conrady, C. D., & Yeh, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081224 · Cited by 39
T cells in ocular autoimmune uveitis: Pathways and therapeutic approaches
Zhang, M., & Zhang, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109565 · Cited by 34
Chen, Z., Zhang, T., Kam, H., Qiao, D., Jin, W., Zhong, Y., Zhou, M., Zhou, H., Chong, W. P., Chen, W., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103496 · Cited by 33
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Both systemic and intravitreal administration of pre-activated Tregs can suppress cell-mediated non-infectious uveitis in animal models (Terrada et al., 2006; Gr ´ egoire et al., 2016).”
CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions
Abraham, A. R., Maghsoudlou, P., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1184937 · Cited by 20
“Nevertheless, intravitreal delivery of polyclonal Tregs has previously demonstrated efficacy in treating a uveitis model in mice (61).”
BackgroundYang, T., Liu, P.-J., Sun, Q.-Y., Wang, Z., Yuan, G.-B., Fan, Z.-X., Ma, L., Lu, J.-F., Yuan, B.-Y., Zou, W.-L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-56739-2 · Cited by 20
Zhang, T., Han, X., Zhong, Y., Kam, H., Qiao, D., Chen, Z., Chan, K. W. Y., Chong, W. P., & Chen, J. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213496 · Cited by 19
Landman, S., de Oliveira, V. L., van Erp, P. E. J., Fasse, E., Bauland, S. C. G., Joosten, I., & Koenen, H. J. P. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-28346-5 · Cited by 16
Regulatory T Cells: Therapeutic Opportunities in Uveitis
Lee, A. Y., & Foulsham, W. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.901144 · Cited by 15
Regulatory T Cell Therapy for Uveitis: A New Promising Challenge
Foussat, A., Grégoire, S., Clerget–Chossat, N., Terrada, C., Asnagli, H., Lemoine, F. M., Klatzmann, D., LeHoang, P., Forte, M., & Bodaghi, B. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2016.0165 · Cited by 15
Self-citationLiu, Y.-H., Mölzer, C., Makinen, K., Kamoi, K., Corbett, C., Klaska, I. P., Reid, D. M., Wilson, H. M., Kuffová, L., Cornall, R. J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02071 · Cited by 14
Huang, Z., Li, W., & Su, W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_11 · Cited by 14
Knutson, O. S., Choi, S., Williams, S., & Calder, V. L. (2025) · Eye · doi:10.1038/s41433-025-03693-6 · Cited by 7
Xiao, S., Yang, Y., Miao, W., Lyu, C., Tao, J., & Yu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.790787 · Cited by 6
Sato, Y., Keino, H., Nakayama, M., Kano, M., & Okada, A. A. (2020) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2020.1757119 · Cited by 5
Progress and Future Perspectives of Treg Cell Therapy
Fang, K., Zong, J., & Chang, X. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl41250 · Cited by 3
Prise en charge diagnostique et thérapeutique des uvéites
Bodaghi, B., Saadoun, D., & LeHoang, P. (2019) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2018.05.001 · Cited by 3
Self-citationWildner, G., & THURAU, S. R. (2024) · Spektrum der Augenheilkunde · doi:10.1007/s00717-023-00563-y · Cited by 2
Landman, S., de Oliveira, V. L., Peppelman, M., Fasse, E., van Rijssen, E., Bauland, S. C. G., van Erp, P. E. J., Joosten, I., & Koenen, H. J. P. M. (2020) · Journal of Immunology Research · doi:10.1155/2020/7680131 · Cited by 2
Bonnet, B. (2017) · theses.fr (ABES) · doi:10.70675/21065805z9d4fz4bfazb0c5z71339db1137f · Cited by 1
Immunologie oculaire: bases physiopathologiques
Terrada, C., Sennlaub, F., & de Kozak, Y. (2017) · doi:10.1016/b978-2-294-74468-6.00002-2
Self-citationNovel Approaches to the Treatment of Noninfectious Uveitis
Smith, J. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-22827-9_14
Novel therapeutic targets in uveitis
Tempest-Roe, S. (2017) · Spiral (Imperial College London) · doi:10.25560/75500
Role of regulatory T cells in pathogenesis and therapeutics of autoimmune uveitis
Patnaik, G., & Biswas, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13947-5.00035-x
Role of regulatory T cells in pathogenesis and therapeutics of autoimmune retinopathy
Patnaik, G., & Biswas, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13947-5.00020-8
Etude du rôle de NF-kB dans les lymphocytes T régulateurs chez la souris
Ronin, É. (2017) · theses.fr (ABES) · doi:10.70675/ea12e750z64e5z437fza120z3bbe647a2642
Li, J., Pang, J., Wu, P., Wang, E., Zheng, S. J., 阮庆国, & Liu, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1881360
Ye, C., Jiang, Q., 蔡秉翰, Jiang, B., & Xie, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms272210128
Xiao, S., Yang, Y., Miao, W., Lyu, C., Tao, J., & Yu, Y. (2022) · doi:10.3389/fphar.2021.790787.s001
Metadata
- Authors
- Grégoire, S., Terrada, C., Martin, G. H., Fourcade, G., Baeyens, A., Marodon, G., Fisson, S., Billiard, F., Lucas, B., Tadayoni, R., Béhar-Cohen, F., Levacher, B., Galy, A., LeHoang, P., Klatzmann, D., Bodaghi, B., & Salomon, B. L.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Paris Cité (FR)
- Université Paris 5, Centre de Recherche des Cordeliers , F-75006 Paris ,
- Inserm (FR)
- Sorbonne Universités, Université Pierre et Marie Curie Univ Paris 06, INSERM, Centre National de la Recherche Scientifique, Centre d’Immunologie et des Maladies Infectieuses (Cimi-Paris) , Laboratoire I3, F-75013 Paris ,
- Corresponding author
- Fourcade, Gwladys
- Baeyens, Audrey
- Marodon, Gilles
- Fisson, Sylvain
- Billiard, Fabienne
- LeHoang, Phuc
- Klatzmann, David
- Bodaghi, Bahram
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-01
- Volume
- 196
- Issue
- 5
- Pages
- 2109-2118
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2252727669
- Cited by
- 33
- References
- 60
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 1
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Keywords
- uveitis, regulatory T cells, Treg therapy, in situ injection, bystander suppression, vitreous humor, IL-10, reactive oxygen species, immune cell infiltration, autoimmune disease, Foxp3
- MeSH terms
- Animals, Disease Models, Animal, Female, Flow Cytometry, Immunotherapy, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Transgenic, Uveitis, T-Lymphocytes, Regulatory, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.